Biocad has received a go-ahead from a key expert panel in India for infliximab, its biosimilar version of Johnson & Johnson's Remicade, amid some confusing signals on the Russian firm’s potential launch plans for the product in the country.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?